Literature DB >> 30511638

Synchronous and metachronous liver metastases in patients with colorectal cancer.

Cecilie Okholm1, Talie Khadem Mollerup, Nicolai Aagaard Schultz, Rune Broni Strandby, Michael Patrick Achiam.   

Abstract

INTRODUCTION: Liver metastases are the most common complication to colorectal cancer, and the presence of metastatic disease severely impacts the overall prognosis of the disease. Since the diagnostic work-up of metastasised colorectal cancer has undergone tremendous changes in past decades, an impact on the incidence of metastatic disease is anticipated. The aim of this study was to evaluate the incidence and prognosis of liver metastasis in patients with colorectal cancer.
METHODS: From 1 January 2005 to 31 December 2011, all patients with a primary diagnosis of colorectal cancer were identified. Data on metastatic dissemination to the liver were collected from medical charts. Patients were followed until death or the end of the study period (31 December 2016).
RESULTS: Among the total study population of 1,672 patients, 23.6% of patients were diagnosed with liver metastases. The incidence of synchronous and metachronous metastases was 16% and 7.7%, respectively. Patients with synchronous and metachronous metastases had a median survival of ten (95% confidence interval (CI): 7.5-12.5) and 43 (95% CI: 35.8-50.2) months, respectively, compared with a median survival of 86 (95% CI: 73.5-98.5) months for patients without liver metastases.
CONCLUSIONS: The incidence of synchronous metastases has remained high despite improved diagnostic technology. Patient survival remains significantly lower when metastatic disease is present, even though treatment options for liver metastases have improved. FUNDING: none. TRIAL REGISTRATION: not relevant. Articles published in the DMJ are “open access”. This means that the articles are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Entities:  

Mesh:

Year:  2018        PMID: 30511638

Source DB:  PubMed          Journal:  Dan Med J        ISSN: 2245-1919            Impact factor:   1.240


  5 in total

Review 1.  Current state of the art imaging approaches for colorectal liver metastasis.

Authors:  Bita Hazhirkarzar; Pegah Khoshpouri; Mohammadreza Shaghaghi; Mounes Aliyari Ghasabeh; Timothy M Pawlik; Ihab R Kamel
Journal:  Hepatobiliary Surg Nutr       Date:  2020-02       Impact factor: 7.293

Review 2.  Current Surgical Management Strategies for Colorectal Cancer Liver Metastases.

Authors:  Gabriel D Ivey; Fabian M Johnston; Nilofer S Azad; Eric S Christenson; Kelly J Lafaro; Christopher R Shubert
Journal:  Cancers (Basel)       Date:  2022-02-20       Impact factor: 6.639

3.  Proteomics and liquid biopsy characterization of human EMT-related metastasis in colorectal cancer.

Authors:  Mao-Sen Huang; Li-Hua Fu; Hao-Chao Yan; Lin-Yao Cheng; Hai-Ming Ru; Si Mo; Chun-Yin Wei; Dai-Mou Li; Xian-Wei Mo; Wei-Zhong Tang; Lin-Hai Yan
Journal:  Front Oncol       Date:  2022-09-28       Impact factor: 5.738

4.  HIF-1α expression in liver metastasis but not primary colorectal cancer is associated with prognosis of patients with colorectal liver metastasis.

Authors:  Yuma Wada; Yuji Morine; Satoru Imura; Tetsuya Ikemoto; Yu Saito; Chie Takasu; Shinichiro Yamada; Mitsuo Shimada
Journal:  World J Surg Oncol       Date:  2020-09-07       Impact factor: 2.754

5.  Effect of Time to Surgery of Colorectal Liver Metastases on Survival.

Authors:  Emerson Y Chen; Skye C Mayo; Thomas Sutton; Matthew R Kearney; Adel Kardosh; Gina M Vaccaro; Kevin G Billingsley; Charles D Lopez
Journal:  J Gastrointest Cancer       Date:  2021-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.